Biogenvs.Neurocrine Biosciences
BIIB vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 2.0× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (22.0 vs 37.2); year to date, Biogen leads (+23.9% vs +7.9%).
Side by side
| BIIB | NBIX | |
|---|---|---|
| Market cap | $31B | $15.5B |
| Price | $220.77 | $153.37 |
| Today | +1.2% | +0.2% |
| Return YTD | +23.9% | +7.9% |
| Return 1Y | +56.6% | +13.0% |
| P/E | 37.2 | 22.0 |
| P/S | 3.1 | 4.6 |
| P/B | 1.6 | 4.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More BIIB & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →